IN THE CLAIMS:

1. (Currently Amended) An oral drug delivery system which comprises a biliquid foam comprising:

from 1 to 20% by weight of a continuous hydrophilic phase,

from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight, said poorly water-soluble drug dissolving in water in an amount of less than 1% by weight, and the biliquid foam including therein from 0.5 to ~~10~~5% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation, wherein the pharmaceutically acceptable oil comprises a mono-, di-, or triglyceride, or a mixture thereof.

2. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase is an aqueous phase.

3. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 2, wherein the aqueous phase is water.

4. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 2, wherein the aqueous phase incorporates a salt or a co-solvent therein.

5. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase is a non-aqueous solvent.

6. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 5, wherein the non-aqueous solvent is an aliphatic alcohol, polyethylene glycol, propylene glycol or glycerol, or mixtures thereof.

7. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the pharmaceutically acceptable oil is a mono-, di- or triglyceride, or a mixture thereof.

8. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 7, wherein the mono-, di- or triglycerides are the glycerol esters of fatty acids containing from 6 to 22 carbon atoms.

9. (Currently Amended) The~~An~~ oral drug delivery system as claimed claim 1, wherein the surfactant comprises an alkyl polyglycol ether, an alkyl polyglycol ester, an ethoxylated alcohol, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene fatty acid ester, an ionic or non-ionic surfactant, a hydrogenated caster oil/polyoxyethylene glycol adduct containing from 25 to 60 ethoxy groups, a castor oil/polyoxyethylene glycol adduct containing from 25 to 45 ethoxy groups, or mixtures thereof.

10. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, which includes therein a co-emulsifier in an amount sufficient to complete the solubilization of the poorly water-soluble drug.

11. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 10, wherein the co-emulsifier is a phosphoglyceride or a phospholipid.

12. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the discontinuous phase comprises from 85 to 96% by weight of the biliquid foam.

13. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 12, wherein the discontinuous phase comprises from 90 to 95% by weight of the biliquid foam.

14. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the continuous hydrophilic phase comprises from 2 to 10% by weight of the biliquid foam.

15. (Cancel)

16. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, wherein the poorly water-soluble drug is an analgesic or anti-inflammatory agent, an anthelmintic, an anti-arrhythmic agent, an anti-coagulant, an anti-depressant, an anti-diabetic, an anti-epileptic, an anti-fungal agent, an anti-gout agent, an anti-hypertension agent, an anti-

malarial, an anti-migraine agent, an anti-muscarinic agent, an anti-neoplastic agent, an anti-protozoal agent, an anti-thyroid agent, an anxiolytic, sedative, hypnotic or neuroleptic agent, a corticosteroid, a dieuretic, an anti-Parkinsonian agent, a gastro-intestinal agent, a histamine H-receptor antagonist, a lipid regulating agent, an anti-anginal agent, a nutritional agent, an opiod analgesic, a sex hormone, a stimulant, or a therapeutic mixture thereof.

17. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, which is in a unit dosage form.

18. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 17, wherein the unit dosage form comprises capsules filled with the biliquid foam.

19. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 18, wherein the capsules are hard or soft gelatin capsules.

20. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, which is in the form of a dilutable concentrate.

21. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 20, which is infinitely dilutable in a co-solvent.

22. (Currently Amended) The~~An~~ oral drug delivery system as claimed in claim 1, for use in a method of treatment by oral administration to the human or animal body.